Simcere closed an out-license deal of 492M USD with Almirall
Nanjing China and Barcelona Spain, September 29, 2022. Simcere Pharmaceutical Group(2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.